Publications
Filters: First Letter Of Title is A [Clear All Filters]
“Achieving accurate estimates of fetal gestational age and personalised predictions of fetal growth based on data from an international prospective cohort study: a population-based machine learning study”, The Lancet Digital Health, vol. 2, no. 7, pp. e368-e375, 2020.
, “ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance”, Wellcome Open Res, vol. 5, p. 13, 2020.
, , , “Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria”, J Infect Dis, vol. 219, no. 9, pp. 1483-1489, 2019.
, , “Adolescents’ perceptions and experiences of pregnancy in refugee and migrant communities on the Thailand-Myanmar border: a qualitative study”, Reproductive health, vol. 15, no. 1, p. 83, 2018.
, “Anopheles Salivary Biomarker as a Proxy for Estimating Plasmodium falciparum Malaria Exposure on the Thailand-Myanmar Border”, Am J Trop Med Hyg, vol. 99, no. 2, pp. 350-356, 2018.
, “Antimalarial drugs for treating and preventing malaria in pregnant and lactating women”, Expert Opin Drug Saf, vol. 17, no. 11, pp. 1129-1144, 2018.
, “Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis”, PLoS medicine, vol. 15, no. 6, p. e1002579, 2018.
, “Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries”, JAMA, vol. 319, no. 21. pp. 2202-2211, 2018.
, “Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum”, Nat Commun, vol. 9, no. 1. p. 2317, 2018.
, “Automated microscopy for routine malaria diagnosis: a field comparison on Giemsa-stained blood films in Peru”, Malaria journal, vol. 17, no. 1, p. 339, 2018.
, “Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients”, PLoS One, vol. 12, no. 2. p. e0168780, 2017.
, “Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum”, Am J Trop Med Hyg, vol. 96, no. 5, pp. 1197-1204, 2017.
, “Asian G6PD-Mahidol reticulocytes sustain normal Plasmodium vivax development”, J Infect Dis, 2017.
, “Accelerated Training of Skilled Birth Attendants in a Marginalized Population on the Thai-Myanmar Border: A Multiple Methods Program Evaluation”, PLoS One, vol. 11, no. 10, p. e0164363, 2016.
, “The acceptability of mass administrations of anti-malarial drug as part of targeted malaria elimination in villages along the Thai-Myanmar border”, Malar J, vol. 15, no. 1, p. 494, 2016.
, “Access to free or low-cost tuberculosis treatment for migrants and refugees along the Thailand-Myanmar border in Tak province, Thailand”, Int J Equity Health, vol. 15, no. 1, p. 100, 2016.
, “Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period”, Sci Rep, vol. 6, p. 32159, 2016.
, “Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria”, N Engl J Med, vol. 375, no. 12, pp. 1152-60, 2016.
, “Artemisinin-Resistant Plasmodium falciparum K13 Mutant Alleles, Thailand-Myanmar Border”, Emerg Infect Dis, vol. 22, no. 8, pp. 1503-5, 2016.
, “Absence of association between Plasmodium falciparum small sub-unit ribosomal RNA gene mutations and in vitro decreased susceptibility to doxycycline”, Malaria Journal, vol. 14, no. 1, p. 348, 2015.
, “Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border”, Clin Vaccine Immunol, vol. 22, no. 3, pp. 319-26, 2015.
, , , “Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria”, Malar J, vol. 13, no. 1, p. 483, 2014.
, “Ancillary Care: From Theory to Practice in International Clinical Research”, Public Health Ethics, vol. 6, no. 2, pp. 154-169, 2013.
, “Antibody boosting and longevity following tetanus immunization during pregnancy”, Clin Infect Dis, vol. 56, no. 5, pp. 749-50, 2013.
, “Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3”, PLoS ONE, vol. 8, no. 2, p. e56061, 2013.
, “Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study”, Lancet Infect Dis, vol. 12, no. 5, pp. 388-396, 2012.
, “Aeromonas spp. Bacteremia in Pregnant Women, Thailand-Myanmar Border, 2011”, Emerg Infect Dis, vol. 18, no. 9, pp. 1522-3, 2012.
, “Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing”, NATURE, vol. 487, no. 7407, pp. 375-9, 2012.
, “Is areca innocent? The effect of areca (betel) nut chewing in a population of pregnant women on the Thai-Myanmar border”, Int Health, vol. 4-172, no. 3, pp. 204-209, 2012.
, “Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial”, Malar J, vol. 11, no. 1, p. 150, 2012.
, “Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother–infant pairs on the Thailand–Burma border”, Clinical Microbiology and Infection, vol. 18, no. 10, pp. 970-975, 2012.
, “The antimalarial ferroquine: from bench to clinic”, Parasite, vol. 18, no. 3, pp. 207-14, 2011.
, “Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries”, Trop Med Int Health, vol. 16, no. 9, pp. 1167-1179, 2011.
, “Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription”, BMC Genomics, vol. 12, no. 1, p. 391, 2011.
, “Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects”, British Journal of Clinical Pharmacology, vol. 73, no. 3, pp. 467-477, 2011.
, “Artemisinin combination therapy for vivax malaria”, Lancet Infect Dis, vol. 10, no. 6, pp. 405-16, 2010.
, “Arthropod borne disease: the leading cause of fever in pregnancy on the Thai-Burmese border”, PLoS Negl Trop Dis, vol. 4, no. 11, p. e888, 2010.
, “Antimalarial therapies in children from Papua New Guinea”, N Engl J Med, vol. 360, no. 12, p. 1254; author reply 1255, 2009.
, “Artemisinin Resistance in Plasmodium falciparum Malaria”, New England Journal of Medicine, vol. 361, no. 5, pp. 455-467, 2009.
, “Artemisinin Resistance in Plasmodium falciparum Malaria (response)”, New England Journal of Medicine, vol. 361, no. 18, pp. 1807-1808, 2009.
, “Adaptive copy number evolution in malaria parasites”, PLOS GENET, vol. 4, no. 10, p. e1000243, 2008.
, “Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic”, Clin Infect Dis, vol. 46, no. 9, pp. 1374-81, 2008.
, “Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax”, J Infect Dis, vol. 198, no. 10, pp. 1558-64, 2008.
, , “Acquired haemophilia A in early pregnancy associated with Plasmodium vivax malaria and hyperthyroidism”, Aust N Z J Obstet Gynaecol, vol. 47, no. 1, pp. 76-7, 2007.
, “Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance”, Lancet Infect Dis, vol. 7, no. 2, pp. 136-44, 2007.
, “Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial”, PLOS CLIN TRIALS, vol. 2, no. 5, p. e20, 2007.
, “Artemisinin-Based Combination Treatment of Falciparum Malaria”, The American Journal of Tropical Medicine and Hygiene, vol. 77, no. 6 Suppl, pp. 181-192, 2007.
, “Antimalarial drugs in pregnancy: a review”, Current Drug Safety, vol. 1, no. 1, pp. 1-16, 2006.
, “Artesunate versus quinine for severe falciparum malaria - Authors' reply”, Lancet, vol. 367, no. 9505, pp. 111-112, 2006.
, “Are Extensive T Cell Epitope Polymorphisms in the Plasmodium falciparum Circumsporozoite Antigen, a Leading Sporozoite Vaccine Candidate, Selected by Immune Pressure?”, J Immunol, vol. 175, no. 6, pp. 3935-9, 2005.
, “Are Transporter Genes Other than the Chloroquine Resistance Locus (pfcrt) and Multidrug Resistance Gene (pfmdr) Associated with Antimalarial Drug Resistance?”, Antimicrob Agents Chemother, vol. 49, no. 6. pp. 2180-2188, 2005.
, “Artemisinin-based combinations”, Curr Opin Infect Dis, vol. 18, no. 6, pp. 531-6, 2005.
, “Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial”, Lancet, vol. 366, no. 9487, pp. 717-25, 2005.
, “Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda”, Trop Med Int Health, vol. 9, no. 4, pp. 445-50, 2004.
, “Artesunate combinations for treatment of malaria: meta-analysis”, Lancet, vol. 363, no. 9402. pp. 9-17, 2004.
, “Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report”, Trans R Soc Trop Med Hyg, vol. 97, no. 5, pp. 592-4, 2003.
, “Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum”, Clinical Infectious Diseases, vol. 33, no. 12, pp. 2009-16., 2001.
, “Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 5, pp. 545-8., 2000.
, “Absence of an interaction between artesunate and atovaquone-proguanil”, European Journal of Clinical Pharmacology, vol. 55, no. 6, pp. 469-74, 1999.
, “Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives”, American Journal of Tropical Medicine and Hygiene, vol. 60, no. 4, pp. 547-55, 1999.
, “Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand”, American Journal of Tropical Medicine and Hygiene, vol. 60, no. 1, pp. 14-21, 1999.
, “Averting a malaria disaster”, The Lancet, vol. 353, no. 9168, pp. 1965-1967, 1999.
, “Averting a malaria disaster (reply)”, The Lancet, vol. 354, no. 9187, pp. 1389-1390, 1999.
, “Artemisinin derivatives in the treatment of falciparum malaria in pregnancy”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 92, no. 4, pp. 430-3., 1998.
, “Artesunate and mefloquine in the treatment of uncomplicated multidrug- resistant hyperparasitaemic falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 92, no. 2, pp. 207-11, 1998.
, “Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria”, American Journal of Tropical Medicine and Hygiene, vol. 59, no. 6, pp. 883-8, 1998.
, “Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 91, no. 5, pp. 574-7, 1997.
, “Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction”, Mol Biochem Parasitol, vol. 85, no. 2, pp. 161-9, 1997.
, “Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 5, pp. 523-7, 1995.
, “Artemisinin: large community studies”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88 Suppl 1, pp. S45-6, 1994.
, “Absorption of intramuscular phenobarbitone in children with severe falciparum malaria”, European Journal of Clinical Pharmacology, vol. 42, no. 1. pp. 107-10, 1992.
,